Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of a Successful Percutaneous Mitral Paravalvular Leak Closure on Long-term Major Clinical Outcomes

  • Belahnech, Yassin|||0000-0003-0723-1023
  • Martí Aguasca, Gerard
  • García del Blanco, Bruno|||0000-0002-4527-1600
  • Ródenas-Alesina, Eduard|||0000-0003-1638-7820
  • González-Alujas, Teresa
  • Gutiérrez García-Moreno, Laura
  • Galian-Gay, Laura|||0000-0001-6828-5928
  • Fernández-Galera, Rubén|||0000-0002-3870-9360
  • Otaegui, Imanol|||0000-0001-6594-3139
  • Serra, Viçens
  • Bellera Gotarda, Neus|||0000-0002-1040-0900
  • Serra, Bernat
  • Calabuig Goena, Alvaro|||0000-0001-8388-4988
  • Calvo-Barceló, Maria
  • Barrabés, José A.|||0000-0001-7062-6277
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
Background: Percutaneous mitral paravalvular leak (PVL) closure techniques are an effective and safe alternative to surgical treatment, but data regarding long-term outcomes are scarce. We aim to describe the impact of successful percutaneous mitral PVL closure on long-term outcomes. Methods: All consecutive patients in whom a first-attempt percutaneous mitral PVL closure was performed in a single tertiary centre between January 2010 and October 2021 were included. Clinical variables, procedural details, and procedural success were collected. Patients were classified based on procedural success, defined as no more than mild residual leak. All-cause mortality was the primary endpoint. Cardiovascular death and heart failure hospitalizations (HFHs) were key secondary endpoints. Results: Ninety patients (median age 72.5 years [66.0-78.4]; median EuroSCORE-II 8.2 [5.3-12.46]) were included. Although reduction of at least 1 degree in PVL severity was achieved in 82 (91.1%), procedural success was achieved in 47 (52.2%). Chronic kidney disease, previous surgery for PVL, and the presence of multiple jets were independently associated with procedural failure. After a median follow-up of 3.2 (1.2-5.2) years, mortality rate was higher in the procedural failure group (27.3 per 100 patients-years) compared with the group with successful closure (8.2 per 100 patient-years). Procedural failure was associated with all-cause death (adjusted hazard ratio [aHR], 2.59; 95% confidence interval [CI], 1.41-4.78), cardiovascular death (aHR, 3.53; 95% CI, 1.67-7.49) and HFH (aHR, 3.27; 95% CI,1.72-6.20). Conclusions: A successful reduction in PVL to mild or absent is associated with improved rates of all-cause death, cardiovascular death, and HFHs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Potential role of closure time with adenosine diphosphate in diagnosis of mitral prosthetic paravalvular leak and prognosis after repair, Utilidad del tiempo de obturación con adenosina difosfato en el diagnóstico de la fuga paravalvular mitral protésica y el pronóstico tras su reparación

  • Belahnech, Yassin|||0000-0003-0723-1023
  • Martí Aguasca, Gerard
  • García del Blanco, Bruno|||0000-0002-4527-1600
  • Ródenas-Alesina, Eduard|||0000-0003-1638-7820
  • Subirà-Ingla, Arnau
  • del Fresno, Sergio
  • Sao-Avilés, Augusto|||0000-0001-8497-0909
  • Solsona-Caravaca, Javier|||0000-0001-6115-7544
  • Galian-Gay, Laura|||0000-0001-6828-5928
  • Fernández-Galera, Rubén|||0000-0002-3870-9360
  • González-Fernández, Víctor
  • Bellera Gotarda, Neus|||0000-0002-1040-0900
  • Serra-García, Vicenc
  • Otaegui, Imanol|||0000-0001-6594-3139
  • Serra, Bernat
  • Calabuig Goena, Alvaro|||0000-0001-8388-4988
  • Soriano-Colomé, Toni|||0000-0002-2121-6084
  • Uribarri, Aitor|||0000-0002-6911-7480
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
Introduction and objectives: Mitral paravalvular leak (PVL) is associated with hemolysis and heart failure. It has also been linked to shear stress-induced von Willebrand factor abnormalities that prolong closure time with adenosine diphosphate (CT-ADP). The aim of this study was to assess whether CT-ADP serves as a biomarker for mitral PVL diagnosis, follow-up, and prognosis after repair. Methods: In this prospective study, 89 patients (27 with moderate-to-severe mitral PVL referred for closure, group 1; 31 with prosthetic mitral valves without PVL, group 2; and 31 controls without valvular disease, group 3) underwent laboratory assessment including hemolysis markers, congestion markers, and CT-ADP. Patients with PVL underwent percutaneous or surgical repair and were followed up at 3 and 12 months. ROC analysis, linear regression, and Cox models were used to evaluate the diagnostic and prognostic value of CT-ADP. Results: CT-ADP was prolonged in PVL patients (median, 214seconds) vs control groups (86 seconds in group 2 and 74seconds in group 3; P <.001). A cutoff of> 135seconds showed excellent diagnostic accuracy (AUROC, 0.96; sensitivity 89%, specificity 97%). Postprocedural CT-ADP decreased significantly after successful repair (median decrease of 79seconds) but remained unchanged in those with residual leaks. Elevated postprocedural CT-ADP (>155 s) identified persistent PVL and was associated with worse 1-year outcomes (HR, 21.37; P=.004), including death, heart failure or hemolysis-related readmission, and reintervention. Conclusions: CT-ADP appears to be a promising biomarker for diagnosing and monitoring mitral PVL. It may add value to conventional markers by reflecting shear stress-related platelet dysfunction and predicting outcomes following PVL closure., Introducción y objetivos: La fuga paravalvular (FPV) mitral se asocia con hemólisis e insuficiència cardíaca, y con alteraciones del factor de von Willebrand que prolongan el tiempo de obturación con adenosina difosfato (TO-ADP). Se evaluó si este puede servir como biomarcador para el diagnóstico, seguimiento y pronóstico tras la reparación de la FPV mitral. Métodos: Se incluyeron prospectivamente 89 pacientes (27 con FPV mitral moderada-grave remitidos para cierre, Grupo 1; 31 con prótesis mitral sin FPV, Grupo 2; y 31 controles sin enfermedad valvular, Grupo 3). Se evaluaron marcadores de hemólisis y congestión y el TO-ADP. Los pacientes con FPV fueron sometidos a reparación y seguidos 3 y 12 meses. Se utilizaron análisis ROC, regresión lineal y modelos de Cox para evaluar el valor diagnóstico y pronóstico del TO-ADP. Resultados: El TO-ADP se prolongó en pacientes con FPV mitral (mediana 214 s) frente a los grupos control (86 s -Grupo 2- y 74 s -Grupo 3-; p < 0,001). Un TO-ADP >135 s mostró excelente precisión diagnóstica (AUROC 0,96; sensibilidad 89%, especificidad 97%). Tras una reparación exitosa, el TO-ADP posprocedimiento disminuyó significativamente (mediana -79 s) y permaneció sin cambios en presencia de fugas residuales. Valores posprocedimiento >155 s identificaron FPV persistente y se asociaron con peores resultados al año (HR 21,37; p = 0,004), incluyendo muerte, reingreso por insuficiencia cardíaca o hemólisis y/o reintervención. Conclusiones: El TO-ADP podría ser un biomarcador prometedor para el diagnóstico y seguimiento de la FPV mitral y podría aportar valor pronóstico tras su reparación.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mid-term outcomes of percutaneous pulmonary valve replacement with Edwards-Sapien bioprosthesis in native right ventricular outflow tract

  • Martí Aguasca, Gerard
  • Ferrer Menduiña, Queralt
  • Giralt-Garcia, Gemma
  • Gonzalez Fernandez, Victor
  • Ferreira González, Ignacio
  • Belahnech, Yassin
  • DOS SUBIRA, LAURA
  • Betrián Blasco, Pedro
  • García del Blanco, Bruno
  • Calvo-Barceló, Maria
  • Ródenas-Alesina, Eduard
  • Pijuan-Domenech, Antonia
  • Gran, Ferran
  • Miranda, Berta
  • Gordon Ramirez, Blanca
  • Barrabés, José A.
  • Roses-Noguer, Ferran
Congenital heart disease; Edwards sapien; Pulmonary valve, Cardiopatia congènita; Edwards Sapien; Vàlvula pulmonar, Cardiopatía congénita; Edwards Sapien; Válvula pulmonar, Information on mid-term outcomes of percutaneous pulmonary valve replacement (PPVR) with the Edwards Sapien (ES) valve in the native right ventricular outflow tract (RVOT) are limited. This study assesses mid-term outcomes in 76 patients who underwent PPVR between 2016 and 2022, comparing native (40.8%) and non-native (59.2%) RVOTs. The primary endpoint was a composite of endocarditis, reinterventions, and cardiovascular death and secondary outcomes included prosthetic valve dysfunction (PVD), tricuspid regurgitation (TR), right ventricular ejection fraction (RVEF), and indexed ventricular volumes. The median patient age was 23.9 years. Pulmonary regurgitation was predominant in the native RVOT group (67.7%), while pulmonary stenosis or combined lesions were more common in the non-native group (90.9%). Procedural success was 98.7%. After a median follow-up of 3.3 years, there was no significant difference in freedom from the primary outcome between groups (87.1% native vs. 93.1% non-native, p = 0.875). Endocarditis and reinterventions occurred at 1.2 per 100 patient-years, and PVD at 3.19 per 100 patient-years, with no differences between groups. A 1-year reduction in ventricular volumes and TR was seen only in the non-native group, with no improvement in RVEF. Overall, PPVR with the ES valve demonstrates satisfactory mid-term outcomes in both native and non-native RVOTs., Yassin Belahnech is supported by a research non-conditioned grant (Rio Hortega CM22/00242) unrelated to the content of this article.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Mid-term outcomes of percutaneous pulmonary valve replacement with Edwards-Sapien bioprosthesis in native right ventricular outflow tract

  • Martí Aguasca, Gerard
  • Ferrer Menduiña, Queralt
  • Giralt-Garcia, Gemma
  • Gonzalez Fernandez, Victor
  • Ferreira González, Ignacio
  • Belahnech, Yassin
  • DOS SUBIRA, LAURA
  • Betrián Blasco, Pedro
  • García del Blanco, Bruno
  • Calvo-Barceló, Maria
  • Ródenas-Alesina, Eduard
  • Pijuan-Domenech, Antonia
  • Gran, Ferran
  • Miranda, Berta
  • Gordon Ramirez, Blanca
  • Barrabés, José A.
  • Roses-Noguer, Ferran
Congenital heart disease; Edwards sapien; Pulmonary valve, Cardiopatia congènita; Edwards Sapien; Vàlvula pulmonar, Cardiopatía congénita; Edwards Sapien; Válvula pulmonar, Information on mid-term outcomes of percutaneous pulmonary valve replacement (PPVR) with the Edwards Sapien (ES) valve in the native right ventricular outflow tract (RVOT) are limited. This study assesses mid-term outcomes in 76 patients who underwent PPVR between 2016 and 2022, comparing native (40.8%) and non-native (59.2%) RVOTs. The primary endpoint was a composite of endocarditis, reinterventions, and cardiovascular death and secondary outcomes included prosthetic valve dysfunction (PVD), tricuspid regurgitation (TR), right ventricular ejection fraction (RVEF), and indexed ventricular volumes. The median patient age was 23.9 years. Pulmonary regurgitation was predominant in the native RVOT group (67.7%), while pulmonary stenosis or combined lesions were more common in the non-native group (90.9%). Procedural success was 98.7%. After a median follow-up of 3.3 years, there was no significant difference in freedom from the primary outcome between groups (87.1% native vs. 93.1% non-native, p = 0.875). Endocarditis and reinterventions occurred at 1.2 per 100 patient-years, and PVD at 3.19 per 100 patient-years, with no differences between groups. A 1-year reduction in ventricular volumes and TR was seen only in the non-native group, with no improvement in RVEF. Overall, PPVR with the ES valve demonstrates satisfactory mid-term outcomes in both native and non-native RVOTs., Yassin Belahnech is supported by a research non-conditioned grant (Rio Hortega CM22/00242) unrelated to the content of this article.